Patients’ treatment and evaluations
cancer, colorectal cancer, mg/mTumor
DISEASE PROGRESSION, COLORECTAL CANCER, ADVERSE EVENT, ADVERSE EVENTS, CANCER, ADVERSE EVENT
The investigator reviewed the sensitivity test report performed in 3D cells, considered specific contraindications and adverse events relevant to the individual patient, and suggested the drug or combination of drugs with the highest relative activity. Patients were only treated with the IndiTreat-guided drug(s) if the test for the specific treatment showed sensitivity in one of the two most sensitive groups. Patient preference, e.g., oral treatment or convenience, was met in the case of clinical equipoise. Standard regimens were administered according to institutional practice for irinotecan and 5FU (FOLFIRI), oxaliplatin and 5FU (FOLFOX), irinotecan, oxaliplatin and 5FU (FOLFOXIRI), and combinations with panitumumab or bevacizumab. For non-standard regimens, the treatment followed the summary of product characteristics. Drugs not explicitly approved for colorectal cancer were administered to the patients using the dosage recommended to other cancer patients.The combination of vinorelbine and capecitabine was given in 3-weekly cycles as oral vinorelbine 80 mg/mTumor response was assessed with CT according to RECIST 1.1. If at the time of the first treatment dose, the baseline scan was older than four weeks, a new CT scan was performed and then repeated every 8 weeks until disease progression. Adverse events were reviewed according to the Common Terminology Criteria for Adverse Events, version 4, before and during treatment.